These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2937870

  • 1. Galactorrhea in DMPA users: incidence and clinical significance.
    Gongsakdi D, Rojanasakul A.
    J Med Assoc Thai; 1986 Jan; 69(1):28-32. PubMed ID: 2937870
    [Abstract] [Full Text] [Related]

  • 2. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M.
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [Abstract] [Full Text] [Related]

  • 3. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M, Guarnaccia M, Alon J, Wiley J.
    Fam Plann Perspect; 1996 Jul; 28(4):174-8. PubMed ID: 8853283
    [Abstract] [Full Text] [Related]

  • 4. Effects of the injectable contraceptive depot medroxyprogesterone acetate in Thai women with liver fluke infestation: final results.
    Grossman RA, Asawasena W, Chalpati S, Taewtong D, Tovanabutra S.
    Bull World Health Organ; 1979 Jul; 57(5):829-37. PubMed ID: 161523
    [Abstract] [Full Text] [Related]

  • 5. A case-control study of breast cancer and hormonal contraception in Costa Rica.
    Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ.
    J Natl Cancer Inst; 1987 Dec; 79(6):1247-54. PubMed ID: 2961909
    [Abstract] [Full Text] [Related]

  • 6. The pituitary reserve for gonadotrophins and prolactin in women under long-term use of depo-medroxyprogesterone acetate (DMPA) as a contraceptive.
    Mukasa FR, Sekadde-kigondu CB, Mati JK, Njoroge JK.
    J Obstet Gynaecol East Cent Africa; 1982 Dec; 1(4):160-3. PubMed ID: 12313677
    [Abstract] [Full Text] [Related]

  • 7. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM.
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [Abstract] [Full Text] [Related]

  • 8. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
    Nelson AL.
    J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB, Noonan L, Whitehead A.
    Bull World Health Organ; 1985 May; 63(3):513-9. PubMed ID: 2931206
    [Abstract] [Full Text] [Related]

  • 10. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C.
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [Abstract] [Full Text] [Related]

  • 11. Continuation of injectable contraceptives in Thailand.
    Narkavonnakit T, Bennett T, Balakrishnan TR.
    Stud Fam Plann; 1982 Apr; 13(4):99-105. PubMed ID: 6216633
    [Abstract] [Full Text] [Related]

  • 12. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome.
    Wortsman J, Hirschowitz JS.
    Obstet Gynecol; 1980 Apr; 55(4):460-3. PubMed ID: 6768040
    [Abstract] [Full Text] [Related]

  • 13. Galactorrhea in oral contraceptive users.
    Holtz G.
    J Reprod Med; 1982 Apr; 27(4):210-2. PubMed ID: 7201522
    [Abstract] [Full Text] [Related]

  • 14. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users.
    Sereepapong W, Chotnopparatpattara P, Taneepanichskul S, Markham R, Russell P, Fraser IS.
    Hum Reprod; 2004 Mar; 19(3):547-52. PubMed ID: 14998949
    [Abstract] [Full Text] [Related]

  • 15. Depot medroxyprogesterone acetate contraception in women with medical problems.
    Frederiksen MC.
    J Reprod Med; 1996 May; 41(5 Suppl):414-8. PubMed ID: 8725704
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of injectable contraceptive users in a low-income population in Texas.
    Sangi-Haghpeykar H, Poindexter AN, Moseley DC, Bateman L, Reid ED.
    Fam Plann Perspect; 1995 May; 27(5):208-11, 225. PubMed ID: 9104608
    [Abstract] [Full Text] [Related]

  • 17. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
    Sanches L, Marchi NM, Castro S, Juliato CT, Villarroel M, Bahamondes L.
    Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732
    [Abstract] [Full Text] [Related]

  • 18. Medroxyprogesterone acetate as an injectable contraceptive.
    Heber KR.
    Aust Fam Physician; 1988 Mar; 17(3):199-201, 204. PubMed ID: 2965570
    [Abstract] [Full Text] [Related]

  • 19. [Injectable contraceptive, DMPA, serum HDL cholesterol and heart infarct].
    Kremer J, de Bruijn HW, Hindriks FR.
    Ned Tijdschr Geneeskd; 1981 Aug 25; 125(35):1418-21. PubMed ID: 6456421
    [Abstract] [Full Text] [Related]

  • 20. [Acceptability of medroxyprogesterone acetate among medical and paramedical personnel in family planning].
    Cervantes A, Velasco Murillo V, Campos Cordero J, Correu Azcona S.
    Ginecol Obstet Mex; 1982 Apr 25; 50(300):85-8. PubMed ID: 6222944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.